10-K: Precipio Inc. Files 10-K Report, Cites Ongoing Concerns About Viability

Precipio Inc.'s 10-K filing reveals a net loss of $5.8 million for 2023 and substantial doubt about the company's ability to continue as a going concern.

Summary

• Precipio Inc. reported a net loss of $5.8 million for the year ended December 31, 2023, and an accumulated deficit of $98.2 million.
• The company's working capital stood at $0.5 million as of December 31, 2023.
• Operating cash flow deficit was $3.6 million for the year ended December 31, 2023.
• The company's independent auditor has expressed substantial doubt about its ability to continue as a going concern.
• Precipio is relying on a sales agreement with AGP to raise up to $5.8 million, of which $0.1 million has been received, and a receivables factoring agreement for funding.
• The company's revenue increased to $15.2 million in 2023, up from $9.4 million in 2022, driven by increased diagnostic testing and product sales.
• The company processed 6,765 cases in 2023, a 65% increase from 4,109 cases in 2022.
• Gross profit increased to $6.0 million in 2023 from $2.5 million in 2022, with gross margin improving to 40% from 27%.

Sentiment

Score: 3

Explanation: The document presents a mixed picture. While there is positive revenue growth and improved gross margins, the substantial net losses, low working capital, and going concern warning from the auditor create a negative outlook. The company's reliance on external funding and the competitive landscape add to the uncertainty.

Positives

• The company experienced a significant increase in revenue, reaching $15.2 million in 2023, a 61% increase from 2022.
• The number of cases processed increased by 65% in 2023, indicating growing demand for the company's diagnostic services.
• Gross profit improved to $6.0 million in 2023, with a gross margin of 40%, up from 27% in 2022, showing improved profitability.
• Operating expenses decreased by $1.7 million in 2023, primarily due to a decrease in stock-based compensation, indicating improved cost management.

Negatives

• The company reported a net loss of $5.8 million for 2023 and has an accumulated deficit of $98.2 million.
• The company's working capital is low at $0.5 million, raising concerns about its short-term financial stability.
• The independent auditor has expressed substantial doubt about the company's ability to continue as a going concern.
• The company is heavily reliant on external funding sources, including a sales agreement with AGP and a receivables factoring agreement.

Risks

• There is substantial doubt about the company's ability to continue as a going concern.
• The company may require significant additional financing to sustain operations.
• Failure to obtain funding may force the company to delay or eliminate product development programs.
• The company has incurred losses since inception and expects to incur losses for the foreseeable future.
• The company is subject to concentrations of revenue and credit risk.
• The company has been, and may continue to be, subject to costly litigation.
• The company's products may not gain market acceptance.
• The company faces intense competition in the diagnostic industry.
• The company may not be able to develop new products or enhance existing systems.
• International expansion could expose the company to various risks.
• Unfavorable economic conditions could adversely affect the company's business.
• The company depends on a limited number of key personnel.
• Cybersecurity risks could compromise the company's information.
• The company's ability to use net operating loss carryforwards is subject to limitations.
• The company faces product liability and personal injury claims risks.
• The company's operations could be impaired by disasters at its laboratories.
• Governmental payers and healthcare plans have taken steps to control costs.
• Changes in payer mix could have a material adverse impact on the company's net sales and profitability.
• The company's laboratories require ongoing CLIA certification.
• The company's products could become subject to government regulations requiring marketing authorization.
• Failure to comply with HIPAA could be costly.
• The company may be subject to the Anti-Kickback Statute, Stark Law, and False Claims Act.
• The company cannot be certain that measures taken to protect its intellectual property will be effective.
• The price of the company's common stock may fluctuate significantly.
• The price of the company's stock may be vulnerable to manipulation.
• The company's securities may be delisted if it cannot satisfy Nasdaq listing requirements.
• Increased costs associated with corporate governance compliance may significantly impact the company's results of operations.
• The company has not paid dividends and does not expect to pay dividends in the foreseeable future.
• The sale or issuance of common stock may cause significant dilution.
• The company is at an increased risk of securities class action litigation.

Future Outlook

The company expects to incur substantial net losses through at least 2024 as it further develops and commercializes its diagnostic technology. The company also expects that its selling, general and administrative expenses will continue to increase due to the additional costs associated with market development activities and expanding its staff to sell and support its products.

Industry Context

The document highlights the problem of misdiagnosis in the cancer diagnostic industry, which is driven by a focus on competitive pricing and test turnaround times at the expense of quality and accuracy. The company aims to address this issue by developing innovative diagnostic products and services that improve accuracy, workflow, and economic outcomes for laboratories. The company competes with both specialized oncology companies and large commercial laboratories, as well as companies in the liquid biopsy market.

Comparison to Industry Standards

• The document mentions competitors such as NeoGenomics, GenPath Diagnostics, Inform Diagnostics, LabCorp, and Quest Diagnostics in the clinical pathology services space.
• In the liquid biopsy market, competitors include Foundation Medicine and Guardant Health.
• For HemeScreen, competitors include Qiagen, BioRad, Ipsogen, Cepheid, Asuragen, Abbott, and Entrogen, which offer single-gene testing assays.
• For NGS panels, competitors include Life Technologies, Illumina, Roche, Natera, PerkinElmer, BioRad, and Qiagen.
• For IV-Cell, competitors include Gibco, Irvine Scientific, Capricorn Scientific, Sigma-Aldrich, and Euroclone, which offer cell culture media and mitogens.
• The company positions HemeScreen as a cost-effective alternative to single-gene testing and NGS panels, and IV-Cell as a unique media that enables simultaneous culturing of all four hematopoietic cell lineages.

Legal Proceedings

• The company is involved in legal proceedings related to matters incidental to its business.
• The company is delinquent on the payment of outstanding accounts payable for certain vendors and suppliers who have taken or threatened to take legal action to collect such amounts.

Stakeholder Impact

• Shareholders face significant risks due to the company's financial instability and potential dilution from future capital raises.
• Employees may be affected by potential cost-cutting measures or restructuring if the company's financial situation does not improve.
• Customers may experience disruptions in service or product availability if the company faces financial difficulties.
• Suppliers and creditors face the risk of non-payment or delayed payments due to the company's financial challenges.

Next Steps

• The company will continue to develop and commercialize its diagnostic technology.
• The company will seek additional funding to meet its obligations and sustain its operations.
• The company will continue to expand its sales force and marketing activities.

Key Dates

Keywords

cancer diagnostics, laboratory testing, molecular diagnostics, HemeScreen, IV-Cell, CLIA laboratory, oncology, misdiagnosis, genetic testing, biotechnology